|
"shan ys"的相关文件
显示项目 116-125 / 133 (共14页)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2016-01 |
A phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma: The TCOG 3211 clinical trial
|
Chen, MH;Lin, J;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-12 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial
|
Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-10 |
Epigenetic regulation in the carcinogenesis of cholangiocarcinoma
|
Chiang, NJ;Shan, YS;Hung, WC;Chen, LT |
| 國家衛生研究院 |
2015-09 |
The safety and efficacy of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan
|
Chou, WC;Liu, CT;Chen, MH;Lu, CH;Ku, FC;Su, YL;Shan, YS;Chen, LT;Chen, YY;Chen, JS |
| 國家衛生研究院 |
2015-08 |
The association between periodontal disease and pancreatic cancer
|
Chang, JS;Tsai, CR;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2015-06 |
Comprehensive analysis of the incidence and survival patterns of lung cancer by histologies, including rare subtypes, in the era of molecular medicine and targeted therapy: A nation-wide cancer registry-based study from Taiwan
|
Chang, JS;Chen, LT;Shan, YS;Lin, SF;Hsiao, SY;Tsai, CR;Yu, SJ;Tsai, HJ |
| 國家衛生研究院 |
2015-05 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
Chen, JS;Hsu, C;Chiang, NJ;Tsai, CS;Tsou, HH;Huang, SF;Bai, LY;Chang, IC;Shiah, HS;Ho, CL;Yen, CJ;Lee, KD;Chiu, CF;Rau, KM;Yu, MS;Yang, Y;Hsieh, RK;Chang, JY;Shan, YS;Chao, Y;Chen, LT |
| 國家衛生研究院 |
2015-05 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial
|
Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-01 |
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E |
| 國家衛生研究院 |
2014-01 |
Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial
|
Chiang, NJ;Hsu, C;Chen, JS;Tsou, HH;Chao, Y;Shan, YS;Huang, SF;Chiu, CF;Lee, KD;Chen, LT |
显示项目 116-125 / 133 (共14页)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
每页显示[10|25|50]项目
|
